Description of Research Expertise:
My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.
Clark Amy S, Karasic Thomas B, DeMichele Angela, Vaughn David J, O'Hara Mark, Perini Rodolfo, Zhang Paul, Lal Priti, Feldman Michael, Gallagher Maryann, O'Dwyer Peter J: Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development. JAMA oncology : 1-8,2015.
Farwell Michael D, Clark Amy S, Mankoff David A: How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy. JAMA oncology 1 (4): 421-2,2015.
Mankoff David A, Farwell Michael D, Clark Amy S, Pryma Daniel A: How Imaging Can Impact Clinical Trial Design: Molecular Imaging as a Biomarker for Targeted Cancer Therapy. Cancer journal (Sudbury, Mass.) 21 (3): 218-24,2015.
DeMichele Angela, Yee Douglas, Berry Donald A, Albain Kathy S, Benz Christopher C, Boughey Judy, Buxton Meredith, Chia Stephen K, Chien A Jo, Chui Stephen Y, Clark Amy, Edmiston Kirsten, Elias Anthony, Forero-Torres Andres, Haddad Tufia C, Haley Barbara, Haluska Paul, Hylton Nola M, Isaacs Claudine, Kaplan Henry, Korde Larissa A, Leyland-Jones Brian, Liu Minetta C, Melisko Michelle, Minton Susan E, Moulder Stacy, Nanda Rita, Olopade Olufunmilayo I, Paoloni Melissa, Park John W, Parker Barbara A, Perlmutter : The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research : 2015.
Clark AS, DeMichele A.: The Cyclin D/Cyclin Dependent Kinase 4/6 Complex as a Target in the Treatment of Breast Cancer. Current Breast Cancer Reports 7 (4): 175-182,2015.
17. DeMichele, A, Natalie Shih, N, Koehler, M, Huang Bartlett, C, Jiang, J, Zhu, Z, Hardwick, J, Huang, D, Zheng, X, Clark, AS, Colameco, C, Driscoll, A, Feldman, M, Gallagher, M, Goodman, N, Huj, H, O'Dwyer, P, Rejto, PA: Upregulation of cell cycle pathway genes without loss of RB1 contributes to acquired resistance to single-agent treatment with Palbociclib in breast cancer. San Antonio Breast Cancer Symposium : 2015.
DeMichele, A, Dickson, M, Clark, AS, Colameco, C, Gallagher, M, Gramlich, K, Zafman, K, Lewis, D, Vaughn, D, Schwartz, G, O’Dwyer, P.: Characterization of Isolated, Uncomplicated Neutropenia, Related to the CDK 4/6 Inhibitor Palbociclib. American Association of Clinical Oncology : 2015.
Clark, AS, O'Dwyer, PJ, Wang, X, Troxel, A, Lal, P, Feldman, MD, Gallagher, M, Driscoll, A, Ndicu, J, Nivar, I, Rosen, MA, Matro, J, Bradbury, AR, Domchek, SM, Fox, KR, DeMichele, A: Palbociclib & paclitaxel on an alternating schedule for advanced breast cancer: Results of a phase Ib trial. San Antonio Breast Cancer Symposium : 2015.
Harding, JJ, Telli, ML, Munster, PM, Le, MH, Molineaux, C, Bennett, MK, Mittra, E, Burris, HA, Clark, AS, Dunphy, M, Meric-Bernstam, F, Patel, MR, DeMichele, A, Infante, JR.: Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. J Clin Oncol 33 (suppl; abstr 2512): 2015.
Silber Jeffrey H, Rosenbaum Paul R, Ross Richard N, Niknam Bijan A, Ludwig Justin M, Wang Wei, Clark Amy S, Fox Kevin R, Wang Min, Even-Shoshan Orit, Giantonio Bruce J: Racial disparities in colon cancer survival: a matched cohort study. Annals of internal medicine 161 (12): 845-54,2014.